While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)
Timeframe: 52 weeks
Tolerance will be evaluated according to their responses on weekly questionnaires
Timeframe: 52 weeks
Adverse Event and/or Serious Adverse Event
Timeframe: 24 weeks